NDA 018965 · Atnahs Pharma US
Naprosyn
Naproxen · Oral · Nonsteroidal Anti-inflammatory Drug
Priority reviewLast checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1987
Mar 23, 1987
Approved uses
1
Original approval plus efficacy supplements
Registered trials
356
90 Phase 3, 11 recruiting
FAERS reports
79,146
63,169 serious, 8,212 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. ( 5.1 ) Naproxen Suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. ( 4 , 5.1 ) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer...
What it is approved for
From the label in effect Jan 5, 2026.
Naproxen Suspension is indicated for: the relief of the signs and symptoms of: rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis tendonitis bursitis acute gout the management of: pain primary dysmenorrhea Naproxen Suspension is a non-steroidal anti-inflammatory drug indicated for: the relief of the signs and symptoms of: rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis tendonitis bursitis acute gout the management of: pain primary dysmenorrhea
Mechanism: Naproxen has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of naproxen, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Naproxen is a potent inhibitor of prostaglandin synthesis in vitro. Naproxen concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because naproxen is an inhibitor of prostaglandin synthesis, its...
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 23, 1987 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
- NAPROSYN · NAPROXEN 25MG/ML · SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Naproxen" as an intervention, any sponsor and status, largest first.
- Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or NaproxenPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00346216 · 24,081 participants · Start Oct 4, 2006 · Primary completion Apr 12, 2016
Drug: celecoxib; Ibuprofen and 1 more · For: Arthritis, Rheumatoid
Sites: Alabaster, Alabama; Bessemer, Alabama; Birmingham, Alabama · 1,066 sites in all
- The Standard Care Versus Celecoxib Outcome TrialPivotal-lookingCompleted
University of DundeeAcademic, hospital or other
NCT00447759 · 7,297 participants · Start Jun 2007 · Primary completion Aug 2015
Drug: Celecoxib; Diclofenac · For: Osteoarthritis; Rheumatoid Arthritis
Sites: Odense, Denmark; Zeist, Netherlands; Aberdeen, United Kingdom · 10 sites in all
- A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or HipPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03161093 · 3,307 participants · Start Aug 17, 2017 · Primary completion Sep 9, 2019
Drug: Fasinumab; Naproxen and 2 more · For: Osteoarthritis, Knee; Osteoarthritis, Hip
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 139 sites in all
- Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or KneePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02528188 · 3,021 participants · Start Jul 21, 2015 · Primary completion Oct 5, 2018
Drug: NSAID; Tanezumab 2.5 mg and 1 more · For: Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 507 sites in all
- Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or HipPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT00809354 · 2,720 participants · Start Feb 12, 2009 · Primary completion Oct 28, 2010
Drug: NSAID; tanezumab and 5 more · For: Osteoarthritis; Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 333 sites in all
- Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)Pivotal-lookingCompleted
Seattle Institute for Biomedical and Clinical ResearchAcademic, hospital or other
NCT00007189 · 2,625 participants · Start Jan 2001 · Primary completion May 2007
Drug: Naproxen Sodium (Aleve); Celecoxib (Celebrex) · For: Alzheimer Disease
Sites: Sun City, Arizona; Tampa, Florida; Baltimore, Maryland · 6 sites in all
- Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of MigrainePivotal-lookingCompleted
Eurofarma Laboratorios S.A.Industry
NCT04384367 · 2,068 participants · Start Dec 30, 2022 · Primary completion Oct 30, 2024
Drug: Rizatriptan 10 mg + Naproxen 550mg; Maxalt 10Mg Tablet and 2 more · For: Migraine
Sites: São Paulo, Brazil · 2 sites in all
- Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With GoutPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02139046 · 1,790 participants · Start Apr 2014 · Primary completion Nov 2015
Drug: Febuxostat IR; Febuxostat XR and 4 more · For: Gout
Sites: Binghamton, Alabama; Birmingham, Alabama; Huntsville, Alabama · 192 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective10,286
- pain9,130
- fatigue7,750
- arthralgia7,621
- nausea7,479
- off label use6,467
- headache6,074
- diarrhoea5,719
- vomiting5,077
- dizziness5,063
- rash4,946
- dyspnoea4,900
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 709 |
| 2005 | 825 |
| 2006 | 810 |
| 2007 | 781 |
| 2008 | 959 |
| 2009 | 1,157 |
| 2010 | 1,448 |
| 2011 | 2,024 |
| 2012 | 2,634 |
| 2013 | 2,544 |
| 2014 | 2,845 |
| 2015 | 3,986 |
| 2016 | 4,944 |
| 2017 | 4,276 |
| 2018 | 5,510 |
| 2019 | 6,942 |
| 2020 | 7,152 |
| 2021 | 5,774 |
| 2022 | 4,858 |
| 2023 | 5,171 |
| 2024 | 5,377 |
| 2025 | 5,370 |
| 2026 | 3,050 |
Recalls
1 FDA enforcement reports for this application.
Apr 20, 2026 · Class II · Ongoing
Chemical contamination; presence of lead and lithium above specification
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Nissen SE, Yeomans ND, Solomon DH, et al. · N Engl J Med 2016 · Multicenter Study, Randomized Controlled Trial
- Naproxen in dysmenorrhoea.
Pauls F · Lancet 1978 · Clinical Trial, Letter
- Herbal formulation "turmeric extract, black pepper, and ginger" versus Naproxen for chronic knee osteoarthritis: A randomized, double-blind, controlled clinical trial.
Heidari-Beni M, Moravejolahkami AR, Gorgian P, et al. · Phytother Res 2020 · Randomized Controlled Trial
- Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
Obeid S, Libby P, Husni E, et al. · Eur Heart J Cardiovasc Pharmacother 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Bombardier C, Laine L, Reicin A, et al. · N Engl J Med 2000 · Clinical Trial, Comparative Study
- Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa.
Reyes-Uribe L, Wu W, Gelincik O, et al. · Gut 2021 · Clinical Trial, Phase I, Multicenter Study
Sponsor: Atnahs Pharma US
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.